Comparison of Leucocyte-rich PRP and Leucocyte-poor PRP in Treating Mild to Moderate Knee Osteoarthritis

Summary

The purpose of this study is to show that there is no difference in patient clinical scores when patients with knee pain are treated with joint application of high dose white blood cell PRP (platelet-rich plasma) and low dose white blood cell PRP for knee osteoarthritis. Participants will be selected based on presenting knee pain lasting for 6 months or longer. Before being recruited, they will undergo radiological examinations (X-ray and MRI), based on which they will be recruited. Before application and subjection to randomization, all patients will fill out clinical questionnaires (KOOS,WOMAC,VAS). Afterwards, the participants will be divided randomly into two groups, one receiving high dose white blood cell PRP and the other group receiving low dose white blood cell PRP. Participants will not be aware of which group they are divided into. They will have blood drawn, the blood will be processed into a PRP blood product. The blood product will then be applied into the joint space with the help of ultrasound. The patients will again fill out clinical scores (KOOS,WOMAC,VAS) at the follow-up intervals (1,3,6,12 months). At the end of the study, participants will be allowed to discover which PRP product they received.

Timeline

Start

2023-11-28

Primary completion

2025-07-18

Completion

2025-10-01

Publications

• Background Dell'Isola A, Allan R, Smith SL, Marreiros SS, Steultjens M. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord. 2016 Oct 12;17(1):425. doi: 10.1186/s12891-016-1286-2.
• Background Le ADK, Enweze L, DeBaun MR, Dragoo JL. Current Clinical Recommendations for Use of Platelet-Rich Plasma. Curr Rev Musculoskelet Med. 2018 Dec;11(4):624-634. doi: 10.1007/s12178-018-9527-7.
• Background Di Martino A, Boffa A, Andriolo L, Romandini I, Altamura SA, Cenacchi A, Roverini V, Zaffagnini S, Filardo G. Leukocyte-Rich versus Leukocyte-Poor Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Trial. Am J Sports Med. 2022 Mar;50(3):609-617. doi: 10.1177/03635465211064303. Epub 2022 Feb 1.
• Background Hong Z, Chen J, Zhang S, Zhao C, Bi M, Chen X, Bi Q. Intra-articular injection of autologous adipose-derived stromal vascular fractions for knee osteoarthritis: a double-blind randomized self-controlled trial. Int Orthop. 2019 May;43(5):1123-1134. doi: 10.1007/s00264-018-4099-0. Epub 2018 Aug 14.
• Background Belk JW, Kraeutler MJ, Houck DA, Goodrich JA, Dragoo JL, McCarty EC. Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Sports Med. 2021 Jan;49(1):249-260. doi: 10.1177/0363546520909397. Epub 2020 Apr 17.
• Background Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011 Oct;39(10):2135-40. doi: 10.1177/0363546511417792. Epub 2011 Aug 16.
• Background Taichman NS, Young S, Cruchley AT, Taylor P, Paleolog E. Human neutrophils secrete vascular endothelial growth factor. J Leukoc Biol. 1997 Sep;62(3):397-400. doi: 10.1002/jlb.62.3.397.
• Background Martin KE, Garcia AJ. Macrophage phenotypes in tissue repair and the foreign body response: Implications for biomaterial-based regenerative medicine strategies. Acta Biomater. 2021 Oct 1;133:4-16. doi: 10.1016/j.actbio.2021.03.038. Epub 2021 Mar 26.
• Background Atri C, Guerfali FZ, Laouini D. Role of Human Macrophage Polarization in Inflammation during Infectious Diseases. Int J Mol Sci. 2018 Jun 19;19(6):1801. doi: 10.3390/ijms19061801.
• Background Fedorova NV, Ksenofontov AL, Serebryakova MV, Stadnichuk VI, Gaponova TV, Baratova LA, Sud'ina GF, Galkina SI. Neutrophils Release Metalloproteinases during Adhesion in the Presence of Insulin, but Cathepsin G in the Presence of Glucagon. Mediators Inflamm. 2018 Feb 14;2018:1574928. doi: 10.1155/2018/1574928. eCollection 2018.
• Background Weirather J, Hofmann UD, Beyersdorf N, Ramos GC, Vogel B, Frey A, Ertl G, Kerkau T, Frantz S. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res. 2014 Jun 20;115(1):55-67. doi: 10.1161/CIRCRESAHA.115.303895. Epub 2014 Apr 30.
• Background Knezevic NN, Candido KD, Desai R, Kaye AD. Is Platelet-Rich Plasma a Future Therapy in Pain Management? Med Clin North Am. 2016 Jan;100(1):199-217. doi: 10.1016/j.mcna.2015.08.014.
• Background Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci. 2020 Oct 21;21(20):7794. doi: 10.3390/ijms21207794.
• Background Dubin J, Leucht P, Murray M, Pezold R; Staff of the American Academy of Orthopaedic Surgeons on Behalf of the Platelet-Rich Plasma (PRP) for Knee Osteoarthritis Technology Overview Workgroup and Contributors. American Academy of Orthopaedic Surgeons Technology Overview Summary: Platelet-Rich Plasma (PRP) for Knee Osteoarthritis. J Am Acad Orthop Surg. 2024 Apr 1;32(7):296-301. doi: 10.5435/JAAOS-D-23-00957. Epub 2024 Jan 30.
• Background Moojen DJ, Everts PA, Schure RM, Overdevest EP, van Zundert A, Knape JT, Castelein RM, Creemers LB, Dhert WJ. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res. 2008 Mar;26(3):404-10. doi: 10.1002/jor.20519.
• Background Degen RM, Bernard JA, Oliver KS, Dines JS. Commercial Separation Systems Designed for Preparation of Platelet-Rich Plasma Yield Differences in Cellular Composition. HSS J. 2017 Feb;13(1):75-80. doi: 10.1007/s11420-016-9519-3. Epub 2016 Aug 19.
• Background Pavlovic V, Ciric M, Jovanovic V, Stojanovic P. Platelet Rich Plasma: a short overview of certain bioactive components. Open Med (Wars). 2016 Aug 12;11(1):242-247. doi: 10.1515/med-2016-0048. eCollection 2016.
• Background Maletic A, Dumic-Cule I, Brlek P, Zic R, Primorac D. Autologous Platelet-Rich Plasma (PRP) for Treating Androgenetic Alopecia: A Novel Treatment Protocol Standardized on 2 Cases. J Clin Med. 2022 Dec 9;11(24):7327. doi: 10.3390/jcm11247327.
• Background Primorac D, Molnar V, Rod E, Jelec Z, Cukelj F, Matisic V, Vrdoljak T, Hudetz D, Hajsok H, Boric I. Knee Osteoarthritis: A Review of Pathogenesis and State-Of-The-Art Non-Operative Therapeutic Considerations. Genes (Basel). 2020 Jul 26;11(8):854. doi: 10.3390/genes11080854.
• Background Connelly AE, Tucker AJ, Kott LS, Wright AJ, Duncan AM. Modifiable lifestyle factors are associated with lower pain levels in adults with knee osteoarthritis. Pain Res Manag. 2015 Sep-Oct;20(5):241-8. doi: 10.1155/2015/389084. Epub 2015 Jun 30.
• Background Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020 Nov 26;29-30:100587. doi: 10.1016/j.eclinm.2020.100587. eCollection 2020 Dec.

Drugs

Indications